External validation of the NADIR model for early prostate-specific antigen response prediction in enzalutamide-treated metastatic hormone-sensitive prostate cancer: An analysis of the ARCHES trial.
CancerSep 27, 2026
Clinical ResearchOncology (Medical)
Soumyajit Roy, Andrew J Armstrong, Neeraj Agarwal et al.
✦ AI-curated · Sources linked
In 30 seconds
This validation study assessed the NADIR model's ability to predict early prostate-specific antigen (PSA) response in 558 enzalutamide-treated patients from the ARCHES trial. The model showed a 64% rate of early favorable PSA response, with an area under the curve of 0.80. Each 10-percentage-point increase in predicted probability correlated with a lower mortality hazard ratio of 0.90.
Key findings
- Early favorable PSA response occurred in 359 patients (64%).
- The area under the receiver operating characteristic curve was 0.80 (95% CI, 0.76-0.83).
- Each 10-percentage-point increase in predicted probability was associated with a hazard ratio of 0.90 for lower mortality.
Why it matters
The NADIR model provides a validated tool for predicting early PSA response in metastatic hormone-sensitive prostate cancer, which is linked to improved overall survival. This can aid in risk stratification and inform treatment decisions.